Funding lifts infant HIE drug race
Fresh financing for an experimental therapy targeting brain injury in newborns has sharpened attention on one of neonatal medicine’s hardest gaps: the absence of any approved drug for hypoxic-ischaemic encephalopathy, or HIE. The trigger…

